周三盘后，窥得儿医药（QuidelOrtho，股票代码：QDEL）股价大涨5.96%，主要受益于公司发布的2025财年第三季度财报优于市场预期。
根据财报显示，尽管总收入同比下降4%至7亿美元，但公司实现了5%的有机销售增长（不包括COVID和美国捐赠者筛查业务）。更值得注意的是，调整后的EBITDA利润率达到25%，同比增加180个基点，这主要得益于超过4000万美元的成本节约措施。调整后的稀释每股收益为0.80美元，较去年同期的0.59美元大幅增长36%。
公司管理层对未来前景持乐观态度，将2025年全年收入指导范围缩小至26.8亿至27.4亿美元，调整后的EBITDA指导范围为5.85亿至6.05亿美元。此外，公司在国际市场表现强劲，特别是中国市场增长5%，受新采购政策影响有限。投资者对公司的成本控制能力、国际市场拓展以及新产品开发进展表示认可，这些因素共同推动了股价的显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.